Enliven CMO exercises options, sells 40,000 shares

Q: How many Enliven (ELVN) shares did the CMO sell and at what prices?

The Form 4 shows sales totaling 40,000 shares of Enliven Common Stock. Weighted average sale prices were reported around $30.02 and $30.19, with individual trades executed in narrow ranges between $30.00 and $30.56 per share.

Q: What option exercise terms did Helen Collins have on her ELVN stock options?

Collins exercised stock options covering 40,000 shares of Enliven Common Stock at an exercise price of $2.48 per share. The Form 4 notes that all shares subject to the option were fully vested and exercisable as of the transaction dates.

Q: Did the Enliven (ELVN) Form 4 include any tax withholding or gift transactions?

No, this Form 4 only reports option exercises and open‑market sales. The transaction summary shows no entries for tax withholding dispositions, gifts, or restructuring transfers, focusing solely on exercise-and-sell activity by the CMO.

Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 40,000 shares of Common Stock at an exercise price of $2.48 per share, then sold 40,000 shares in open‑market trades at weighted average prices around $30.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 40,000 shares of Common Stock at an exercise price of $2.48 per share, then sold 40,000 shares in open‑market trades at weighted average prices around $30.

The transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 19, 2025. After these trades, Collins holds 25,000 shares of Enliven Therapeutics Common Stock directly.

Insider Trade Summary 10b5-1

Exercise and Sale: 40,000 shares ($1.10M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Collins Helen Louise

Role CHIEF MEDICAL OFFICER

Sold 40,000 shs ($1.20M)

Approx. gross sale proceeds $1.20M

Approx. exercise cost $99K

Approx. pre-tax spread $1.10M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,129	$0.00	$0.00
Exercise	Common Stock	10,129	$2.48	$25K
Sale	Common Stock	10,129	$30.1932	$306K
Exercise	Stock Option (right to buy)	29,871	$0.00	$0.00
Exercise	Common Stock	29,871	$2.48	$74K
Sale	Common Stock	29,871	$30.0228	$897K

Holdings After Transaction: Stock Option (right to buy) — 181,268 contracts (Direct); Common Stock — 25,000 shares (Direct)

Footnotes (6)

F1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F5. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Enliven Therapeutics (ELVN) CMO Helen Collins report on this Form 4?

Helen Collins reported exercising options for 40,000 Enliven shares and selling 40,000 shares in open‑market transactions. The filing also shows she now directly holds 25,000 shares of Enliven Therapeutics Common Stock following these trades.

Were Helen Collins’ ELVN stock transactions pre-planned under a Rule 10b5-1 plan?

Yes, the option exercises and related sales were executed under a Rule 10b5‑1 trading plan adopted on October 19, 2025. Such plans schedule trades in advance, making the timing more routine and less reflective of short‑term expectations.

How many Enliven (ELVN) shares did the CMO sell and at what prices?

The Form 4 shows sales totaling 40,000 shares of Enliven Common Stock. Weighted average sale prices were reported around $30.02 and $30.19, with individual trades executed in narrow ranges between $30.00 and $30.56 per share.

What option exercise terms did Helen Collins have on her ELVN stock options?

Collins exercised stock options covering 40,000 shares of Enliven Common Stock at an exercise price of $2.48 per share. The Form 4 notes that all shares subject to the option were fully vested and exercisable as of the transaction dates.

How many Enliven Therapeutics (ELVN) shares does the CMO own after these transactions?

Following the reported exercises and sales, Helen Collins directly owns 25,000 shares of Enliven Therapeutics Common Stock. This post‑transaction holding figure comes from the Form 4’s “shares following transaction” entries for her non‑derivative Common Stock.

Did the Enliven (ELVN) Form 4 include any tax withholding or gift transactions?

No, this Form 4 only reports option exercises and open‑market sales. The transaction summary shows no entries for tax withholding dispositions, gifts, or restructuring transfers, focusing solely on exercise-and-sell activity by the CMO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/11/2026 - 05:32 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Helen Louise

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER

80301

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/09/2026		M⁽¹⁾		29,871	A	$2.48	54,871⁽²⁾	D
Common Stock	03/09/2026		S⁽¹⁾		29,871	D	$30.0228⁽³⁾	25,000⁽⁴⁾	D
Common Stock	03/10/2026		M⁽¹⁾		10,129	A	$2.48	35,129⁽²⁾	D
Common Stock	03/10/2026		S⁽¹⁾		10,129	D	$30.1932⁽⁵⁾	25,000⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.48	03/09/2026		M⁽¹⁾			29,871	⁽⁶⁾	06/17/2031	Common Stock	29,871	$0	191,397	D
Stock Option (right to buy)	$2.48	03/10/2026		M⁽¹⁾			10,129	⁽⁶⁾	06/17/2031	Common Stock	10,129	$0	181,268	D

Explanation of Responses:

1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

5. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

	/s/ Ben Hohl, by power of attorney	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR